ReviewDiagnostics (Basel, Switzerland)2025
Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment.
Review in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Study of CD36 receptor gene expression in obese and non-obese chronic kidney disease patients.Molecular biology reports · 2026Article
- Effects of chronic jetlag on high-fat and high-fructose diet induced renal injury in mice.Scientific reports · 2026Article
- Obesity-related glomerulopathy, A growing kidney burden in the obesity pandemic.Clinical and experimental nephrology · 2026Review
- Obesity and Its Clinical Implications in End-Stage Kidney Disease.Medicina (Kaunas, Lithuania) · 2026Review
- Chronic kidney disease as an active driver of digestive tract tumors: mechanistic insights and emerging management strategies.Frontiers in cell and developmental biology · 2026Review
- Recurrent Weight Gain after Metabolic Bariatric Surgery (MBS): Emerging Insights on Kidney Function.Obesity surgery · 2026Review
- Novel Therapeutic Strategies for Obesity-Related Glomerulopathy.Current hypertension reports · 2025Review
- High-Fat-Diet-Induced Kidney Injury in Rats: The Role of Tart Cherry Supplementation.Antioxidants (Basel, Switzerland) · 2025Article
- Beneficial Effects of Butyrate on Kidney Disease.Nutrients · 2025Review
- Rhein ameliorates inflammation, gut dysbiosis, and renal injury in obesity-related glomerulopathy mice.Frontiers in pharmacology · 2025Article
- Harnessing gut-derived bioactives and AI diagnostics for the next generation of type 2 diabetes solutions.Frontiers in endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity has emerged as a global epidemic with far-reaching health complications, including its role as an independent risk factor for chronic kidney disease (CKD). Increasing evidence suggests that obesity contributes to CKD through multiple mechanisms, including chronic inflammation, hemodynamic alterations, insulin resistance, and lipid accumulation. These processes can culminate in histopathological changes collectively referred to as obesity-related glomerulopathy (ORG). This review aims to provide a comprehensive overview of the current knowledge regarding the prevalence, clinical manifestations, and pathophysiology of ORG. Furthermore, we emphasize the importance of identifying key biomarkers that facilitate the early detection of ORG. Finally, we explore emerging therapeutic strategies that offer promise in mitigating this growing global health crisis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.